Research ExplorerPublicationsTyrosine kinase inhibitors improve long-term outcome of allo...

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Standard

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. / Brissot, Eolia; Labopin, Myriam; Beckers, Marielle M; Socié, Gérard; Rambaldi, Alessandro; Volin, Liisa; Finke, Jürgen; Lenhoff, Stig; Kröger, Nicolaus; Ossenkoppele, Gert J; Craddock, Charles F; Yakoub-Agha, Ibrahim; Gürman, Günhan; Russell, Nigel H; Aljurf, Mahmoud; Potter, Michael N; Nagler, Armon; Ottmann, Oliver; Cornelissen, Jan J; Esteve, Jordi; Mohty, Mohamad.

In: HAEMATOLOGICA, Vol. 100, No. 3, 01.03.2015, p. 392-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brissot, E, Labopin, M, Beckers, MM, Socié, G, Rambaldi, A, Volin, L, Finke, J, Lenhoff, S, Kröger, N, Ossenkoppele, GJ, Craddock, CF, Yakoub-Agha, I, Gürman, G, Russell, NH, Aljurf, M, Potter, MN, Nagler, A, Ottmann, O, Cornelissen, JJ, Esteve, J & Mohty, M 2015, 'Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia', HAEMATOLOGICA, vol. 100, no. 3, pp. 392-9. https://doi.org/10.3324/haematol.2014.116954

APA

Brissot, E., Labopin, M., Beckers, M. M., Socié, G., Rambaldi, A., Volin, L., Finke, J., Lenhoff, S., Kröger, N., Ossenkoppele, G. J., Craddock, C. F., Yakoub-Agha, I., Gürman, G., Russell, N. H., Aljurf, M., Potter, M. N., Nagler, A., Ottmann, O., Cornelissen, J. J., ... Mohty, M. (2015). Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. HAEMATOLOGICA, 100(3), 392-9. https://doi.org/10.3324/haematol.2014.116954

Vancouver

Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. HAEMATOLOGICA. 2015 Mar 1;100(3):392-9. https://doi.org/10.3324/haematol.2014.116954

Bibtex

@article{71fb5e3ba2bb4dbc9688db6577fb52e9,
title = "Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia",
abstract = "This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting.",
author = "Eolia Brissot and Myriam Labopin and Beckers, {Marielle M} and G{\'e}rard Soci{\'e} and Alessandro Rambaldi and Liisa Volin and J{\"u}rgen Finke and Stig Lenhoff and Nicolaus Kr{\"o}ger and Ossenkoppele, {Gert J} and Craddock, {Charles F} and Ibrahim Yakoub-Agha and G{\"u}nhan G{\"u}rman and Russell, {Nigel H} and Mahmoud Aljurf and Potter, {Michael N} and Armon Nagler and Oliver Ottmann and Cornelissen, {Jan J} and Jordi Esteve and Mohamad Mohty",
note = "Copyright{\textcopyright} Ferrata Storti Foundation.",
year = "2015",
month = mar,
day = "1",
doi = "10.3324/haematol.2014.116954",
language = "English",
volume = "100",
pages = "392--9",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "3",

}

RIS

TY - JOUR

T1 - Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

AU - Brissot, Eolia

AU - Labopin, Myriam

AU - Beckers, Marielle M

AU - Socié, Gérard

AU - Rambaldi, Alessandro

AU - Volin, Liisa

AU - Finke, Jürgen

AU - Lenhoff, Stig

AU - Kröger, Nicolaus

AU - Ossenkoppele, Gert J

AU - Craddock, Charles F

AU - Yakoub-Agha, Ibrahim

AU - Gürman, Günhan

AU - Russell, Nigel H

AU - Aljurf, Mahmoud

AU - Potter, Michael N

AU - Nagler, Armon

AU - Ottmann, Oliver

AU - Cornelissen, Jan J

AU - Esteve, Jordi

AU - Mohty, Mohamad

N1 - Copyright© Ferrata Storti Foundation.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting.

AB - This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting.

U2 - 10.3324/haematol.2014.116954

DO - 10.3324/haematol.2014.116954

M3 - SCORING: Journal article

C2 - 25527562

VL - 100

SP - 392

EP - 399

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 3

ER -